BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 20203178)

  • 1. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
    Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
    J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
    Oueslati A
    J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
    Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
    J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease.
    Oueslati A; Paleologou KE; Schneider BL; Aebischer P; Lashuel HA
    J Neurosci; 2012 Feb; 32(5):1536-44. PubMed ID: 22302797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
    Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.
    Laferrière F; He X; Zinghirino F; Doudnikoff E; Faggiani E; Meissner WG; Bezard E; De Giorgi F; Ichas F
    Cells; 2020 Oct; 9(11):. PubMed ID: 33138150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.
    Waxman EA; Giasson BI
    J Neuropathol Exp Neurol; 2008 May; 67(5):402-16. PubMed ID: 18451726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
    Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
    Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
    Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
    Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of In Vitro Multi-Serine Phosphorylation of Alpha-Synuclein in Aggregation and Cytotoxicity.
    Chaturvedi M; Raj R; Yadav SK; Srivastava T; Devi S; Dharmadana D; Valéry C; Sharma SK; Kumar D; Priya S
    ACS Chem Neurosci; 2023 Sep; 14(17):3103-3112. PubMed ID: 37562012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
    Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
    PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
    Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
    Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synucleinopathies: clinical and pathological implications.
    Galvin JE; Lee VM; Trojanowski JQ
    Arch Neurol; 2001 Feb; 58(2):186-90. PubMed ID: 11176955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.
    Peng C; Gathagan RJ; Covell DJ; Medellin C; Stieber A; Robinson JL; Zhang B; Pitkin RM; Olufemi MF; Luk KC; Trojanowski JQ; Lee VM
    Nature; 2018 May; 557(7706):558-563. PubMed ID: 29743672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 123I-MIBG scintigraphy and phosphorylated α-synuclein skin deposits in synucleinopathies.
    Giannoccaro MP; Donadio V; Giannini G; Devigili G; Rizzo G; Incensi A; Cason E; Calandra-Buonaura G; Eleopra R; Cortelli P; Liguori R
    Parkinsonism Relat Disord; 2020 Dec; 81():48-53. PubMed ID: 33049589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.